Development of AI Model for Renal Tumor Diagnosis Using CT and Lab Tests

Completed

• Conditions: Renal Tumors

• Registration Number: NCT06761742
• Lead Sponsor: RenJi Hospital

Brief Summary

This multi-center retrospective study aims to develop a multimodal artificial intelligence diagnostic model using preoperative contrast-enhanced CT images and routine laboratory parameters from patients with renal tumors. The model is designed to assist clinicians in accurately predicting the pathological subtypes of renal tumors preoperatively, enabling detailed diagnoses and advancing precision medicine.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-01-01
• Status Verified: 2024-12
• Primary Completion: 2024-12-01
• Study Completion: 2024-12-01
• Study First Submitted: 2024-12-30
• Study First Submitted QC: 2024-12-30
• Last Update Submitted: 2024-12-30
• Study First Posted: 2025-01-07
• Last Update Posted: 2025-01-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1922

Inclusion Criteria

• Underwent renal tumor resection with a complete postoperative pathological report, and the pathological diagnosis is one of the following types: clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, renal angiomyolipoma, or renal oncocytoma.
• Complete and available four-phase contrast-enhanced CT scans prior to surgery.
• Complete and available routine laboratory test results prior to surgery.

Exclusion Criteria

• Incomplete CT data or poor image quality that affects diagnostic analysis.
• A time interval of more than three months between imaging or laboratory testing and pathological diagnosis.
• Patients diagnosed with fat-rich renal angiomyolipoma (AML).
• Pathological diagnosis indicating the coexistence of two or more pathological types of renal tumors.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
postoperative pathological report	From the time of surgery to the release of the postoperative pathological report (typically within 2 weeks post-surgery).

Trial Locations

Locations (1)

Shanghai Jiaotong University School of Medicine, Renji Hospital; 🇨🇳 Shanghai, Shanghai, China